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Leukemic Epstein–Barr virus (EBV)-associated post-transplant 
lymphoproliferative diseases (PTLD) following allogeneic hematopoietic stem cell 
transplantation are extremely rare. We can successfully treat an EBV-associated 
leukemic lymphoma patient with rituximab, cidofovir, and donor lymphocyte infusion 
(DLI). In the present case, EBV-specific T cells that were present in the peripheral blood 
before rituximab administration treatment rapidly increased after DLI in association 
with a decrease in the EBV-DNA load.  
 
1. Why this case is important 
EBV-PTLD following allogeneic hematopoietic stem-cell transplantation presents with 
serious complications. Among them, leukemic lymphoma is extremely rare but could be 
fatal, and appropriate treatments are currently unknown. Here we report a successful 
case of treating EBV-associated leukemic lymphoma with rituximab, cidofovir, and DLI 
in addition to our previous treatment experience of EBV-associated leukemic 
lymphoma. 
 
2. Case description 
Case 1 
A 34-year-old woman was diagnosed with severe aplastic anemia (AA) in 1997. 
Although she received anti-thymocyte globulin (ATG) along with cyclosporin (CsA) 
and androgen therapy, her AA progressed. In 2012, she received an allogeneic bone 
marrow transplantation (BMT) from an unrelated donor who was an HLA match except 
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one HLA-DRB1 allele (recipient HLA, A 24:02/33:03, B 48:01/51:01, Cw 08:03/14:02, 
DRB1*09:01/09:01; donor HLA, A 24:02/33:03, B 48:01/51:01 Cw 08:03/14:02 
DRB1*09:01/11:01). The conditioning regimen included total-body irradiation (TBI) (2 
Gy on day −1), total-lymphoid irradiation (TLI) (3 Gy on day 0), fludarabine (Flu) (30 
mg/m2/day on days −5, −4, −3, and −2), cyclophosphamide (CY) (25 mg/kg/day on 
days −5, −4, −3, and −2), and ATG (Thymoglobulin, 2.5 mg/kg/day on day −5 and −4). 
Prophylaxis for graft-versus-host disease (GVHD) consisted of tacrolimus (from day 
−1) and short-term methotrexate (5 mg/m2/day on days 1, 3, and 6). Both donor and 
recipient were EBV positive before transplantation. The neutrophil count surpassed 
500/µl on day 16 after BMT. She developed a high fever, systemic lymphadenopathy, 
and hepatosplenomegaly on day 38. The WBC count was 3790/µl with 4% leukemic 
lymphocytes that were positive for EBV-encoded mRNA, as demonstrated by in situ 
hybridization and donor type cells by chimerism analysis. Flow cytometry (FCM) of 
peripheral-blood lymphocytes revealed that virtually all B cells expressed CD19+, 
CD20+ and Igκ. The EBV-DNA copy number was 23970/ml of blood and 48000/ml of 
serum. EBV clonality was confirmed by Southern blotting using the EBV 
terminal-repeat probe and an IgH PCR assay. sIL-2R level was 1523 U/ml and 
anti-EBV antibody titer was as follows: EBV anti-VCA IgG, 80×; EBV anti-VCA IgM, 
<10×; EBV anti EA-DR IgG, <10×; EBV-anti EBNA, 10×. Although a bone-marrow 
aspiration (BMA) was not performed because of her severe condition on day 38, BMA 
study showed 11% leukemic lymphocytes in bone marrow on day 40 after rituximab 
treatment. She was therefore diagnosed as having EBV-associated leukemic lymphoma. 
Following discontinuation of tacrolimus on day 38, we treated the patient with 
rituximab (375 mg/m2/day on days 38, 42, 47, 54, and 86), cidofovir (5 mg/kg/day on 
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days 41 and 48), and DLI (1 × 106 CD3+ cells/kg on day 46), after the approval by the 
Institutional Review Board of Kanazawa University. No renal impairment was observed 
after the cidofovir treatment. The blood CD19+ atypical lymphocyte count decreased to 
0/µl on day 48, and her systemic lymphadenopathy resolved. However, the CD8+ 
HLA-DR+ lymphocyte count increased to 10230/µl on day 53. Detection of 
EBV-specific cytotoxic T cells was performed according to the previous report1.The 
FCM analysis using an HLA-A24 tetramer revealed 1% of the CD8+ T cells to be 
EBV-specific cytotoxic T cells, which were markedly increased compared with 
EBV-specific CD8+ T cells in pre-BMT blood (0.1%, day −10), post-rituximab 
treatment blood (0.2%, day 42), and the donor lymphocyte inoculum (0.1%) (Figure 1). 
Cytomegalovirus (CMV)-specific CD8+ T cells also increased from 0.1% 
(pre-transplant) to 1.5% after the DLI. CMV antigenemia that occurred on day 31 was 
no longer detected after day 56. EBV-DNA in blood decreased from 13860 copies/ml on 
day 45, to 203 copies/ml on day 52, 204 copies/ml on day 95, and became undetectable 
on day 116. Grade I (skin stage 1) acute GVHD developed 6 days after DLI but was 
remitted without additional treatments. No signs of chronic GVHD were observed. 
Although there is persistent B-cell lymphocytopenia (60–120/µl) with 
hypogammaglobulinemia (IgG levels 220–470 mg/dl), the patient is alive without 
relapse of either EBV-PTLD or AA as of September, 2015.  
 
Case 2 
An 18-year-old man was diagnosed with severe B-cell acute lymphoblastic 
leukemia (B-ALL) in 2007. Although induction chemotherapy according to the 
JALSG-ALL202U protocol2 induced a CR, his ALL relapsed during the maintenance 
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chemotherapy in 2008. A reinduction chemotherapy that consisted of high-dose 
cytarabine (4 g/m2/day × 3 days), pirarubicin (40 mg/m2/day × 5 days), and etoposide 
(100 mg/ m2/day × 5 days) failed to induce a CR. Because no HLA fully-matched 
donors were found from either relatives or the Japanese marrow donor program (JMDP), 
he received an allogeneic peripheral-blood stem-cell transplantation (PBSCT) from his 
46-year-old mother who was HLA-two loci mismatched (recipient HLA, A 02:07/11:01, 
B 46:01/52:01, DRB1*01:01/09:01; donor HLA, A 02:07/11:01, B 40:01/46:01, 
DRB1*09:01/14:05). The conditioning regimen consisted of etoposide (30 mg/ m2/day 
on days −9 and −8), busulphan (3.2 mg/kg/day on days −7 and −6), melphalan (70 mg/ 
m2/day on days −5 and −4), TBI (1 Gy/day on days −4 and −3), and ATG 
(Thymoglobulin, 2.5 mg/kg/day on days −3 and −2). Prophylaxis for GVHD consisted 
of tacrolimus (from day −1) and methylprednisolone (40 mg/day, from day 1). The 
recipient was pre-transplant EBV positive. The neutrophil count surpassed 500/µl on 
day 10 after PBSCT and the complete hematopoietic donor chimerism was confirmed 
on day 24. On day 49, atypical lymphocytes (118/µl, 2% of WBC 5900/µl) appeared in 
the peripheral blood. On day 53 he developed a persistent high fever, systemic 
lymphadenopathy, and splenomegaly; the WBC count was 2100/µl with 11% atypical 
lymphocytes and chimerism analysis revealed that they were donor type cells. A 
bone-marrow study was not performed because of his severe condition. The clonality of 
CD19+/CD20+ cells of his peripheral blood was confirmed by the predominant Igκ 
expression using FCM. The EBV-DNA copy number was 600,000/ml of blood. He was 
diagnosed to have EBV-associated leukemic lymphoma, and was treated with DLI on 
day 53 (5 × 105 CD3+ cells/kg) and on day 58 (1 × 106 CD3+ cells/kg) in addition to 
rituximab (375 mg/m2 on day 57). Tacrolimus was discontinued from day 55. Despite 
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these treatments, the number of atypical lymphocytes increased to 4082/µl accounting 
for 13% of WBC. FCM of peripheral blood on day 59 revealed no CD19+/CD20+ cells 
and an increase in the CD8+ cell count to 8095/µl. His liver and renal injuries 
deteriorated and he died of multiple organ failure on day 59. Any symptoms of GVHD 
were not observed during his clinical course. 
 
3. Other similar and contrasting cases in the literature 
Comoli et al reported four cases of CD20-/CD19+ B cells in peripheral blood, 
accompanied by overt PTLD in 3 patients after haploidentical stem-cell transplantation. 
The latter cleared PTLD after receiving donor EBV-specific cytotoxic T lymphocytes 
(CTLs), and persist in remission at a median 30-month follow-up3.  
 
4. Discussion 
EBV-PTLD is rare, but is considered to be one of the most serious complications after 
allogeneic stem-cell transplantation. The fatality rate of EBV-PTLD has been reported 
to be 50%–92%4-7.  Before the rituximab era, unmanipulated DLI was the only 
effective treatment for EBV-PTLD, although DLI was not potent enough to cure 
EBV-PTLD and often induced severe GVHD. The effect of DLI is believed to be 
mediated by T cells specific to EBV specific epitopes such as EBV-BMLF1, 
EBV-BRLF1, and EBV-EBNA3A8. Although Comoli et al showed that EBV-specific 
T-cell frequency was restored by EBV-specific CTLs therapy for EBV-PTLD to levels 
comparable with controls, they evaluated EBV-specific T-cell frequency indirectly using 
IFN-γ secretion from lymphocytes by ELISPOT assay or flow cytometry3. This is, to 
our knowledge, the first report to confirm the increase of EBV-specific cytotoxic T cells 
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using EBV-tetramers after DLI and rituximab treatment directly. Muramatsu et al 
reported that EBV-tetramer-positive CD8+ cells were detected in the peripheral blood of 
a patient after radiation and rituximab treatment for EBV-PTLD9. In our case, 
EBV-specific T cells that had been present in the peripheral blood before rituximab 
treatment rapidly increased after DLI in association with a decrease in the EBV-DNA 
load. This clinical course clearly shows that EBV-specific T cells played a substantial 
role in eradicating EBV-PTLD.  
We experienced four leukemic EBV-PTLD cases (0.5%) among the 797 who 
received allogeneic stem-cell transplantation (alloSCT) from 1991 to 2013 at our 
institutes10, 11 (Table 1). All four patients received ATG-conditioning regimens and it is 
well known that these regimens induce EBV diseases post-alloSCT due to the level of 
immunosuppression12. Patriarca et al demonstrated that CD4+ T-cell counts <50/µl at 
day +30 post-alloSCT were significantly associated with an increased risk of high-load 
EBV-DNAemia (>10000 copies/ml) in alloSCT patients in whom 68% received ATG in 
their conditioning regimen13. Our case 1 patient’s CD4+ T-cell counts were also < 50/µl 
at day +30 post-alloSCT. Two of the four patients with leukemic EBV-PTLD were 
treated with DLI or DLI plus rituximab but did not show treatment response; both died 
due to progressive disease. In the latter case (Case 2) the delayed rituximab 
administration might have been the cause of the progressive disease. Because 
monotherapy with rituximab is reported to rescue 63% patients with PTLD14, we 
expected that rituximab therapy would not be able to cure a fulminant EBV- PTLD as 
seen in our case even in combination with DLI. Cidofovir, a monophosphate nucleotide 
analogue of cytosine that inhibits viral DNA polymerase, is effective in treating various 
kinds of viral infections due to adenovirus15, BK virus16, and EBV17-19. Although the 
8 
 
addition of cidofovir to rituximab-DLI therapy may have helped the patient to overcome 
such a disastrous condition without obvious adverse effects, there is little evidence to 
suggest therapeutic efficacy against EBV14, 20. It is therefore reasonable to consider 
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Analysis of EBV specific CD8+ T cells in peripheral blood. Before bone marrow 
transplant (day -10) (A), donor lymphocytes inoculum (B), post-rituximab treatment 
(day 42) (C) and post- DLI (day 53) (D). EBV: Epstein-Barr virus, CMV: 

























allo-SCT (days) Outcome Cause of death Reference









(skin) None 1264+ 1302+ Alive NA Our case







230 Rituximab, DLI None NA 6 59 Dead Progression of PTLD Our case







15800 DLI None NA 11 56 Dead Progression of PTLD (11)
4 1992 38 Female AML (M2) CY+Bu→mPSL+ATG BM MMRD (1 HLA-DR mismatch) Not assessed 1800 None None NA 8 19 Dead
Development of
PTLD, fungal sepsis (10)
EBV-PTLD: Epstein-Barr virus-associated post-transplant lymphoproliferative diseases, allo-SCT: allogeneic stem cell transplantation, AA: aplastic anemia, B-ALL: B-cell acute lymphoblastic leukemia, AML: acute myeloid leukemia, Flu: fludarabine, CY:
cyclophosphamide, ATG: anti-thymocyte globulin, TLI: total lymphoid irradiation, TBI: total body irradiation,  Mel: melphalan, iBu: intravenous busulfan, ETP: etoposide, Bu: oral busulfan, mPSL: methylprednisolone, BM: bone marrow, PB: peripheral blood, MMURD:
mismatched unrelated donor, MMRD: mismatched related donor, DLI: donor lymphocyte infusion, GVHD: graft-versus-host disease, NA: not applicable.
Table 1. Outcome and treatments of the patients with leukemic EBV-PTLD

